HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Halozyme Therapeutics (HALO) Tops Q1 EPS by 10c, Beats on Revenue; Offers Guidance
May 7, 2024 4:05 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.79, $0.10 better than the analyst estimate of $0.69. Revenue for the quarter came in at $196 million versus the consensus estimate of $199.74 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90. Halozyme Therapeutics sees FY2024... More
